

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

IRW

April 4, 2005

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1646  
Patent Application  
Docket No. UF-375  
Serial No. 10/602,394

 Margaret Efron, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : *Not yet assigned*  
Art Unit : 1646  
Applicant(s) : Carrie Haskell-Luevano  
Serial No. : 10/602,394  
Filed : June 23, 2003  
Conf. No. : 1696  
For : Novel Melanocortin Receptor Templates, Peptides, and Use Thereof

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.56, 1.97, AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. The applicant is also attaching a copy of the Partial International Search Report received in the foreign communication.

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.56, 1.97, and 1.98 are met by the foregoing statements.


Respectfully submitted,



Margaret Efron  
Patent Attorney  
Registration No. 47,545  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32606-6669

MHE/la

Attachments: Form PTO/SB/08;  
Copies of references cited; and  
Copy of Partial International Search Report



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/602,394
Filing Date	June 23, 2003
First Named Inventor	Carrie Haskell-Luevano
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	UF-375

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R1	Han, G., J.M. quillan, K. Carlson, W. Sadée, V.J. Hruby (February 27, 2003) "Design of Novel Chi8meric Melanotropin-Deltrophin Analogues. Discovery of the First Potent Human Melanocortin 1 Receptor Antagonist" <i>J. Med. Chem.</i> 46:810-819.
	R2	Joseph, Christine G., Andrzej Wilczynski, Jerry R. Holder, Zhimin Xiang, Rayna M. Bauzo, Joseph W. Scott, Carrie Haskell-Luevano (December 2003) "Chimeric NDP-MSH and MTII melanocortin peptides with agouti-related protein (AGRP) Arg-Phe-Phe amino acids possess agonist melanocortin receptor activity" <i>Peptides</i> 24(12):1899-1908.
	R3	Szardenings, Michael et al. (October 31, 1997) "Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1" <i>Journal of Biological Chemistry</i> 272(44):27943-27948.
	R4	Wilczynski, Andrzej, Xiang S. Wang, Christine G. Joseph et al. (April 22, 2004) "Identification of Putative Agouti-Related Protein (87-132)-Melanocortin-4 Receptor Interactions by Homology Molecular Modeling and Validation Using Chimeric Peptide Ligands" <i>J. Med. Chem.</i> 47(9):2194-2207.
	R5	
	R6	
	R7	
	R8	
	R9	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.